2. Done by Ghassan Al-Maimani

3. Conduct venous return from gut and associated organs to the liver. Much of the system is retroperitoneal but some tributaries are within mesentery. Supplies approximately 75% of hepatic blood supply. Portal vein is about 8 cm in length, 11 mm in diameter.

5. Formed at level of second lumbar vertebra by junction of the superior mesenteric & splenic veins. Union of these veins taking place in front of IVC & behind the neck of the pancreas.

6. It passes upward behind the 1 st part of the duodenum & then ascends in the Rt border of the lesser omentum to the Rt extremity of porta hepatis where it divides into right & left branches, which accompany the corresponding branches of the hepatic artery into substance of the liver.

7.  SMV  Splenic vein  Coronary vein  Cystic vein  Para umbilical veins - IMV - Pancreatic veins - Left gastroepiploic vein - Short gastric veins. - Intestinal veins - Ileocolic vein - Rt colic vein - Middle colic vein - Inferior pancreatico- douodenal vein - Rt gastro epiploic vein

8. Portal HTN It is an increase in the pressure within portal vein ≥ 12 mmHg (normal pressure 5-10mmHg)

9. Pathophysiology increase in vascular resistance to the portal blood flow which determined by blood vessels radius ( small decrease in vessel radius → large increase in portal vascular resistance ). increase in portal blood flow which is established through splanchinc arteriolar VD caused by an excessive release of endogenous vasodilators

11. 1.Portal vein thrombosis. 2.Splenic vein thrombosis. 3.Extrinsic compression ( tumor ). 4.Stenosis of portal vein. 5.Splanchnic arteriovenous fistula.

12. 1.Schistosomiasis. 2.Primary biliary cirrhosis. 3.Myeloproliferative disease. 4.Hepatic metastasis. 5.Granulomatous disease ( sarcoidosis, TB). 1.Hepatic cirrhosis. 2.Acute alcoholic hepatitis. 3.Acute fulminant hepatitis. 4.Congenital hepatic fibrosis. 5.Vitamine A toxicity.

13. 1.Budd-chiari syndrome. 2.IVC obstruction. 3.Constrictive pericarditis. 4.Rt heart failure.

15. 1.Esophageal anastomosis: * azygos vein (caval ) * left coronay vein ( portal ) 2. Paraumbilical anastomosis : * epigastric veins (caval ) * parambilical veins ( portal ) 3. Rectal anastomosis : * inferior & middle hemonhoidal (caval ) * superior hemonhoidal ( portal ) 4. Retroperitoneal anastomosis : * retroperitonal parietal vein (caval ) * Visceral vein of Retzius ( portal )

16. History from a patient with portal hypertension should be directed towards determining the cause of portal hypertension and, secondarily, the presence of the complications of portal hypertension.

17.  - Determining the cause of portal hypertension involves the following: - History of jaundice - History of blood transfusions, intravenous drug use (hepatitis B and C) - Pruritus - Family history of hereditary liver disease (hemochromatosis, Wilson disease) - History of alcohol abuse

18.  - Determining the presence of the complications of portal hypertension involves the following: - Hematemesis or melena (gastroesophageal variceal bleeding or bleeding from portal gastropathy) - Mental status changes - Increasing abdominal girth (ascites) - Abdominal pain and fever [SBP] - Hematochezia (bleeding from portal colopathy)

19. - Dilated veins in the anterior abdominal wall - Venous pattern on the flanks - Caput medusa - Rectal hemorrhoids - Ascites - Paraumbilical hernia  - Signs of portosystemic collateral formation include the following:

20.  - Signs of liver disease include the following: - Ascites - Jaundice - Spider angiomas - Palmar erythema -Asterixis - Testicular atrophy - Gynecomastia - Dupuytren contracture - Muscle wasting - Splenomegaly

21.  - Signs of hyperdynamic circulatory state include the following: - Bounding pulses - Warm, well-perfused extremities - Arterial hypotension

22. Lab studies are directed towards investigating etiologies of cirrhosis, which is the most common cause of portal HTN - Liver function tests - Prothrombin time - Albumin - Viral hepatitis serologies - Platelet count - Antinuclear antibody, antimitochondrial antibody, antismooth muscle antibody - Iron indices - Alpha1-antitrypsin deficiency - Ceruloplasmin,

23. - Ultrasound (US) is a safe, economical, and effective method for screening for portal hypertension. - Features suggestive of hepatic cirrhosis with portal hypertension include the following: Nodular liver surface is suggestive. Splenomegaly is a suggestive finding. Patients may demonstrate the presence of collateral circulation.  - Duplex-Doppler ultrasonography

24. - CT scan is a useful qualitative study in cases where sonographic evaluations are inconclusive. - Findings suggestive of portal hypertension include the following: Collaterals arising from the portal system are suggestive of portal hypertension. Dilatation of the IVC also is suggestive of portal hypertension.  - CT scan :-

25. - MRI provides qualitative information similar to CT scan when Doppler findings are inconclusive.  - Magnetic resonance imaging  - Liver-spleen scan - This is described for historical interest only. - Liver-spleen scan uses technetium sulfur colloid taken up by cells in the reticuloendothelial system. - A colloidal shift from the liver to the spleen or bone marrow is suggestive of increased portal pressure.

26. Selective angiography of the superior mesenteric artery or splenic artery with venous return phase.

27. - The most commonly used method is measurement of the hepatic venous pressure gradient (HVPG), which is an indirect measurement that closely approximates portal venous pressure. - A fluid-filled balloon catheter is introduced into the femoral or internal jugular vein and advanced under fluoroscopy into a branch of the hepatic vein. Free hepatic venous pressure (FHVP) then is measured. The balloon is inflated until it is wedged inside the hepatic vein, occluding it completely, thus equalizing the pressure throughout the static column of blood. The occluded hepatic venous pressure (ie, wedged hepatic venous pressure) minus the unoccluded, or free, portal venous pressure (ie, FHVP) is the HVPG.  Hemodynamic measurement of portal pressure

28. –Perform upper endoscopy, as appropriate, to screen for varices in every patient with suggestive findings of portal hypertension. – Gastroesophageal varices confirm the diagnosis of portal hypertension; however, their absence does not rule it out. –Various indirect indices, such as platelet count, spleen size, albumin, and Child- Pugh score, have been studied to help diagnose varices without endoscopy.  Endoscopy

29. - A recent case review study revealed some of these predictors as unreliable. For the time being, endoscopy remains the criterion standard for screening patients with cirrhosis for varices. -In compensated patients without varices, repeat endoscopy at 2- to 3-year intervals to evaluate for the development of varices. - In compensated patients with small varices, repeat endoscopy at 1- to 2-year intervals to evaluate the progression of varices.

30. Endoscopic appearance of esophageal varices

31. -The Child-Pugh classification is used to assess the prognosis of chronic liver disease, mainly cirrhosis - It consists of 2 parts : - It consists of 2 parts : - laboratory : bilirubin and albumin - laboratory : bilirubin and albumin - clinical : encephalopathy, ascites, PT - clinical : encephalopathy, ascites, PT

32. < 22 – 3> 3 > 3.52.8 – 3.5< 2.8 1 – 34 – 6> 6 NoneSlightModerate NoneMinimalAdvanced

33. Gastroesophageal variceal hemorrhage is the most dramatic and lethal complication of portal hypertension; therefore, most of the following discussion focuses on the treatment of variceal hemorrhage - General measures - Medical - Endoscopic - Surgical

34.  admit to ICU.  obtain iv access.  resuscitation: prompt but do not overdo it. Blood : Aim Hb = 8 g/dl NS  FFP for coagulopathy ( bring INR < 1.4 )  Platelets for sever thrombocytopenia ( bring PLT > 50,000)  Intubation-prior to endoscopy ( for airway prophylaxis).

35. -Improve survival ( meta-analysis ) -  rebleeding. -  infections. - Norfloxacin 400 mg po bid 7 days.

36. -Splanchnic VCs. - reduce inflow into portal vein. - somatostatin + analogues :- octreotide. + analogues :- octreotide. - vasopressin + analogues :- terlipressin. + analogues :- terlipressin.

37. No effect on mortality. reduce rebleeding when added to endoscopic therapy. 50 mcg/h bolus, 3-5 days.

38. Very potent splanchnic VC Unaceptable side effects :- - cardiac ischemia. - peripheral ischemia. - Bowel ischemia. - arrhythmia.

39. -reduce portal and collateral blood flow -Splanchnic vasoconstriction -Propranolol is administered at a dose of 20 mg every 12 h -A recent meta-analysis of 11 trials evaluating nonselective beta-blockers in the prevention of first variceal bleeding shows that the bleeding rate in controls (25%) is significantly reduced (to 15%) in patients treated with beta-blockers after a median follow-up of 24 months -Beta-blockers are best continued for the patient's lifetime because the risk of variceal hemorrhage returns to that of the untreated population once beta-blockers are withdrawn

40. Perform within 12 h After resuscitation / intubation. band ligation is better than sclerotherapy for control of bleeding and rebleeding.

41. Occludes venous channels. Multiple sessions + surveillance. > 60 % rebleed. 1 3 fail Rx. Less complication Vs sclerotherapy Rx. Endoscopic Rx of choice.

43. Intra- or Para- Variceal Occludes venous channels Multiple sessions + surveillance >60% rebleed 1/3 fail treatment 30% complication rate

44. IntravaricealParavariceal

45. LOCALUlcerationStricturePerforation SYSTEMICFeverPneumonitisCNS

46. Balloon-tube tamponade The Minnesota tube The Minnesota tube is an adaptation of the Sengstaken-Blakemore (S-B) tube, the difference is that the S-B tube does not have the esophageal suction port to prevent aspiration

47. Total shunt. Selective shunt. Partial shunt. Non-shunt.

48. End to Side PortocavalSide to Side Portocaval Interposition ShuntsCentral Splenorenal

49. Prevent rebleed > 90% Thrombosis with graft Encephalopathy rate 40%

50. Goals: Prevent variceal bleeding and encephalopathy Mechanism: Decompress Varices Maintain Portal Perfusion Maintain Portal Hypertension Key: Decompress only gastrosplenic compartment

52. Mean follow-up 39 mos (1-8 yrs)

53. Ease of portocaval Limited portal diversion Maintain some liver perfusion

55. Options Esophageal transection Variceal ligation Devascularize +/- splenectomy Very limited role

56. Indicated for liver failure Not for variceal bleeding Number  > 3,500/yr in U.S. 20,000 potential recipients in U.S. 5,000 listed for transplant 24% die on waiting list

59. Technically feasible Complications 9 - 50% Infection Intraperitoneal Bleeding Congestive Failure Subcapsular Hematoma Acute Renal Failure Hemobilia Mortality (30 day) 3 - 13%

60. Encephalopathy minimum 15% Occlusion 33 - 73% at one year Rebleeding 18% at one year 19% at 4.7 months

61. Severe encephalopathy RHF or pulmonary HTN Advanced liver failure Portal vein thrombosis with cavernous transformation

62. Child A better than Child C Start Sandostatin when Dx suspected β blockade  bleeding by  C.O Banding safer than scleroTx TIPS: Encephalopathy & occlusion rate Selective shunt:  encephalopathy

65. Sodium / Water Restriction Spironolactone Loop Diuretic Large Volume Paracentesis Peritoneal-Venous Shunt (?) TIPS

66. References Feldman M, Scharschmidt B, Zorab R, eds: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management. Philadelphia, Pa: WB Saunders; 1998. Garcia-Pagan JC, Bosch J: Medical treatment of portal hypertension. Baillieres Best Pract Res Clin Gastroenterol 2000 Dec; 14(6): 895-909. Samonakis DN, Triantos CK, Thalheimer U: Management of portal hypertension. Postgrad Med J 2004 Nov; 80(949): 634-41. Schiff ER, Sorrell MF, Maddrey WC, eds: Schiff's Diseases of the Liver. Philadelphia, Pa: Lippincott-Raven; 1999. Sherlock S, Dooley J, eds: Diseases of the Liver and Biliary System. Oxford, UK: Blackwell Science; 1997. Wongcharatrawee S, Groszmann RJ: Diagnosing portal hypertension. Baillieres Best Pract Res Clin Gastroenterol 2000 Dec; 14(6): 881-94